Monodispersed Sirolimus-Loaded PLGA Microspheres with a Controlled Degree of Drug–Polymer Phase Separation for Drug-Coated Implantable Medical Devices and Subcutaneous Injection by Zilin Zhang (4370773)

“…Nearly 15% of the total drug was released by the initial burst release during an accelerated drug release testing performed at 37 °C using a hydrotropic solution containing 5.8 M <i>N</i>,<i>N</i>-diethylnicotinamide. After 24 h, 71% of the drug was still entrapped in the particles. …”

Top 50 up-regulated genes in <i>lin-35(n745</i>), mutant in starved L1 animals. by Ashwin Seetharaman (615458)

Overexpression of CCP5A and CCP5B induced flagellum length decrease and cell cycle defects. by Louise Basmaciyan (4576624)

Differences in abundance of non-lipid molecules in liver of <i>Fmo5</i>^<i>-/-</i> and WT mice. by Ian R. Phillips (5074121)

“…Red dots are non-lipids that are significantly increased or decreased in <i>Fmo5</i>^<i>-/-</i> mice with a -log₁₀ <i>q</i> above 1.301 (<i>q</i> <0.05) (grey line). …”

AMPK phosphorylation and AC5 and AC6 gene expression in hearts from WT and AMPKα2-/- mice following TAC. by Anne Garnier (130125)

Subjects:

The difference in average sensitivities between the inside and outside of CVH (⊿RSo-i) in eyes with CNV (CNV+, n = 6) or without CNV (CNV−, n = 6). by Rion Ozawa (13155216)

Stability parameters for SpGrx3 WT and mutants. by Trang Van Tran (16913946)

Kinetic parameters of SpGrx3 WT and mutants. by Trang Van Tran (16913946)

An Allosteric Modulator of RNA Binding Targeting the N‑Terminal Domain of TDP-43 Yields Neuroprotective Properties by Niloufar Mollasalehi (9511076)

“…<i>In silico</i> docking of 50K compounds to the NTD domain of TDP-43 identified a small molecule (nTRD22) that is bound to the N-terminal domain. …”

Modeled structures of C1-RhoGAP domain of WT PARG1, I845V and T622M mutants. by Zen Kouchi (14898435)

Main components of bauxite and BCFD (wt.%). by Nian Liu (29935)

<i>Ang1</i>-KO mice develop more severe colitis compared to WT mice. by Alexander Hu (14755811)

Juxtanuclear endosomal distortion in cells expressing Vpu-S52,56N-APEX2. by Charlotte A. Stoneham (10819125)

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

N1-specific anti-serum decreases replication of A(H1N1)pdm09 in HAE cells. by Anouk Smet (713884)

Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer by Fan-Fan Shang (16953264)

“…Derivative <b>A11</b> directly binds to the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) protein with a <i>K</i>_D value of 2.88 nM, which is about 23-fold more potent than CuB, leading to the decreased expression of downstream apoptosis- and cell cycle-related proteins. …”

2‑Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2) by Ariel L. Burgio (15069256)

“…Our studies revealed <b>SLB1122168</b> (<b>33p</b>), which is a potent inhibitor (IC₅₀ = 94 ± 6 nM) of Spns2-mediated S1P release. …”

Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3‑Oxo-3,4-dihydro‑2<i>H</i>‑ben... by Shuhei Ikeda (2380180)

“…Optimization of the left hand side afforded <b>4f</b> as a promising reversible MAGL inhibitor, which showed potent in vitro MAGL inhibitory activity (IC₅₀ 6.2 nM), good oral absorption, blood–brain barrier penetration, and significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3–10 mg/kg, po. in mice.…”